Abrocitinib: A comprehensive review of its use in dermatology beyond atopic dermatitis.
Janus kinase (JAK) inhibitors are small molecule inhibitors that restrict proinflammatory pathways and are used in various autoimmune and inflammatory conditions, thus gaining significant threshold in dermatology. Abrocitinib, a JAK 1 inhibitor, was first approved in 2021 for use in atopic dermatiti...
| Publicado en: | Indian Journal of Skin Allergy Vol. 4; no. 1; pp. 1 - 19 |
|---|---|
| Autores principales: | , |
| Formato: | review tables/charts Journal Article |
| Publicado: |
Scientific Scholar LLC
Jan-Jun2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |